Hasse Khiabani Zaré

  • Group leader; MD, PhD
  • +47 23 07 08 98
 

Publications 2020

Egeland EJ, Witczak BJ, Zare HK, Christensen H, Asberg A, Robertsen I (2020)
Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease
Clin. Pharmacol. Ther., 108 (4), 866-873
DOI 10.1002/cpt.1875

Publications 2019

Skulberg AK, Asberg A, Khiabani HZ, Rostad H, Tylleskar I, Dale O (2019)
Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial
Addiction, 114 (5), 859-867
DOI 10.1111/add.14552

Publications 2017

Strand TE, Khiabani HZ, Boico A, Radiloff D, Zhao YL, Hamilton KL, Christians U, Klawitter J, Noveck RJ, Piantadosi CA, Bell C, Irwin D, Schroeder T (2017)
The novel combination of theophylline and bambuterol as a potential treatment of hypoxemia in humans
Can. J. Physiol. Pharmacol., 95 (9), 1009-1018
DOI 10.1139/cjpp-2016-0635

Publications 2008

Hegstad S, Khiabani HZ, Kristoffersen L, Kunoe N, Lobmaier PP, Christophersen AS (2008)
Drug screening of hair by liquid chromatography-tandem mass spectrometry
J. Anal. Toxicol., 32 (5), 364-372
DOI 10.1093/jat/32.5.364

Publications 2007

Hegstad S, Khiabani HZ, Oiestad EL, Berg T, Christophersen AS (2007)
Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS
J. Anal. Toxicol., 31 (4), 214-219
DOI 10.1093/jat/31.4.214